X
DFTX

Xponance’s Definium Therapeutics DFTX Stock Holding History

Xponance’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,015
Closed -$17K – 1214
2022
Q1 		$17K Sell
1,015
-84
-8% -$1.46K ﹤0.01% 1158
2021
Q4 		$23K Buy
1,099
+8
+0.7% +$255 ﹤0.01% 1163
2021
Q3 		$38K Sell
1,091
-84
-7% -$3.63K ﹤0.01% 1159
2021
Q2 		$61K Buy
+1,175
New +$61.7K ﹤0.01% 1227

Other funds holding DFTX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Xponance's DFTX Position: Q2 2022 in Review

Xponance sold out of Definium Therapeutics (DFTX) in Q2 2022, closing a stake of 1,015 shares — an estimated $17K sold.

Xponance first reported a position in DFTX in Q2 2021 and held it in 4 quarters. The position peaked at $61K in Q2 2021. 155 funds tracked by Wall St. Rank hold DFTX as of Q2 2022.

  • Xponance reported no remaining Definium Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Xponance sold 1,015 Definium Therapeutics shares in Q2 2022, an estimated $17K.
  • Xponance first reported a position in Definium Therapeutics in Q2 2021 and held it in 4 quarters.
  • Xponance's Definium Therapeutics position peaked at $61K in Q2 2021.
  • 155 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2022.

Based on Xponance's 13F filing for Q2 2022, filed 2 Aug 2022.